Telemedicine Enabling Patients in Self-care Behaviors

September 21, 2021 updated by: Kathleen Fasing, University of Michigan
The purpose of the study is to see if monthly telemedicine computer visits (visits using the computer) improve the time it takes to identify and treat an arrhythmia. The second purpose is to see if monthly telemedicine computer visits improves the participant's understanding of the arrhythmia and improves how the participant feels with daily activities.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Study will utilize the Telemedicine group and the Standard Visit group (30 patients each group) to determine

Endpoints:

  1. Time of recognition, time of diagnosis and time of intervention for arrhythmia. These times will be noted for each patient in each group and look for any difference in these times based upon gaining information from telemedicine visits versus 6 month follow up visit.
  2. Three surveys of patient Self efficacy of medications, activity, and arrhythmia knowledge utilizing three surveys in each group. Surveys will be answered at the start of the study and end of the study by every patient within each group.

Surveys:

MUSE- Medication Understanding and Self Efficacy Tool Shortened FSES- Functioning self efficacy scale ASTA- Arrhythmia specific symptoms and health related quality of life in connection with heart rhythm disturbance

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • University of Michigan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Read and speak English
  • 18 years of age or older
  • Have a cardiac arrhythmia diagnosis
  • Are willing to participate in the study and answer a pre and post survey.

Exclusion Criteria:

  • Any difficulty in understanding the study
  • Does not have internet or a cell phone data plan
  • Any life threatening arrhythmias
  • Objection to working with nurse practitioners and physician assistants

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Standard of care group
Discuss new arrhythmias, review symptoms, discuss methods to help symptoms, questions and answers, monitor devices every 3 months
Other: Standard of care group
Visits every 6 months is standard of care.
Other Names:
  • Telemedicine
Experimental: Telemedicine group
Discuss new arrhythmias, review symptoms, discuss methods to help symptoms, questions and answers, monitor devices every 3 months
Behavioral: Telemedicine group
Conduct monthly telemedicine 'skype' visit
Behavioral: Telemedicine
Review details of medication indication and use, activity recommendations and changes, and knowledge of arrhythmia changes and activities which are helpful with arrhythmia changes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time of recognition of an arrhythmia
Time Frame: Up to 6 months
Patient recognition of a probable arrhythmia
Up to 6 months
Time of diagnosis of arrhythmia
Time Frame: Up to 6 months
Time of diagnosis of arrhythmia by medical staff- at what point is the diagnosis present.
Up to 6 months
Time to treatment initiation of arrhythmia
Time Frame: Up to 6 months
The time- what point in time is the treatment plan innitiated
Up to 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in self efficacy in medication use score as measured by the Medication Self Efficacy Tool (MUSE) survey
Time Frame: Baseline, 6 months
MUSE is 7 items which are evaluated to identify if the patient has a good overall understanding and perception of their medicine.
Baseline, 6 months
Change in functioning self efficacy score as measured by the 13 Item Shortened Function Self-efficacy Scale (FSES)
Time Frame: Baseline, 6 months
The FSES is 13 questions with responses scored from 1 to 5 with a maximum score of 65. Higher scores indicates higher level of functioning.
Baseline, 6 months
Change in self-efficacy of arrhythmia management score as measured by the Arrhythmia-Specific questionnaire in Tachycardia and Arrhythmias (ASTA) survey
Time Frame: Baseline, 6 months

The ASTA questionnaire is divided into three separate parts.

  • Part 1 is descriptive data that evaluates the patient's latest episode of arrhythmia and his/her pharmaceutical treatment.
  • Part 2 has 9 items and a four point's response scale with response alternatives from 0 to 3: "No (0), Yes, to a certain extent (1), Yes, quite a lot (2) or Yes, a lot (3) ". A summarized score is calculated for the items, a higher score implies higher symptom burden due to the heart rhythm disturbance. Scoring for the ASTA symptom burden scale ranges from 0 (least burdensome) to highest 27 (most burdensome).
  • Part 3 scale has 13 items and describes the arrhythmia's influence on daily life with a seven items physical subscale (items 1-5, 10 and 12) and a six items mental subscale (items 6-9, 11 and 13). The response alternatives from 0 to 3: "No (0), Yes, to a certain extent (1), Yes, quite a lot (2),
Baseline, 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Michigan

Investigators

  • Principal Investigator: Kathleen Fasing, University of Michigan
  • Study Chair: Hakan Oral, MD, University of Michigan

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 26, 2020

Primary Completion (Actual)

August 10, 2021

Study Completion (Actual)

September 20, 2021

Study Registration Dates

First Submitted

February 28, 2020

First Submitted That Met QC Criteria

March 3, 2020

First Posted (Actual)

March 5, 2020

Study Record Updates

Last Update Posted (Actual)

September 22, 2021

Last Update Submitted That Met QC Criteria

September 21, 2021

Last Verified

September 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HUM00156966

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Arrythmia

Clinical Trials on Standard of care group

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe